Free Trial

UroGen Pharma (NASDAQ:URGN) Posts Quarterly Earnings Results, Misses Estimates By $0.11 EPS

UroGen Pharma logo with Medical background
Remove Ads

UroGen Pharma (NASDAQ:URGN - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11), Zacks reports. The firm had revenue of $24.57 million for the quarter, compared to analyst estimates of $25.25 million.

UroGen Pharma Price Performance

UroGen Pharma stock traded up $0.08 on Thursday, reaching $10.90. The company's stock had a trading volume of 222,570 shares, compared to its average volume of 377,910. The company has a market cap of $255.65 million, a price-to-earnings ratio of -3.46 and a beta of 1.12. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The business's fifty day moving average price is $10.45 and its 200 day moving average price is $11.70. UroGen Pharma has a twelve month low of $9.03 and a twelve month high of $20.70.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a "buy" rating and a $31.00 price objective on the stock. D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a research note on Monday. Finally, HC Wainwright reduced their target price on UroGen Pharma from $64.00 to $55.00 and set a "buy" rating on the stock in a report on Tuesday. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, UroGen Pharma currently has a consensus rating of "Buy" and an average target price of $38.20.

Remove Ads

View Our Latest Stock Report on UroGen Pharma

Insider Activity at UroGen Pharma

In related news, General Counsel Jason Drew Smith sold 7,379 shares of the firm's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the sale, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by company insiders.

UroGen Pharma Company Profile

(Get Free Report)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

See Also

Earnings History for UroGen Pharma (NASDAQ:URGN)

Should You Invest $1,000 in UroGen Pharma Right Now?

Before you consider UroGen Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.

While UroGen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

SMCI’s Rally Isn’t Over – Here’s Why It Could Hit $100!
7 Flying Car Stocks to Buy Before the Sector Really Takes Off
Institutions Are Dumping These 3 Stocks—Should You?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads